A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

Abstract Background Chronic limb-threatening ischemia (CLTI) represents the final stage of peripheral arterial disease. Approximately one-third of patients with CLTI are not eligible for conventional surgical treatments. Furthermore, patients with advanced stage of CLTI are prone to amputation and d...

Full description

Bibliographic Details
Main Authors: Martha L. Arango-Rodríguez, Ligia C. Mateus, Claudia L. Sossa, Silvia M. Becerra-Bayona, Víctor Alfonso Solarte-David, Miguel Enrique Ochoa Vera, Lady T. Giratá Viviescas, Ana M. Vera Berrio, Sergio Eduardo Serrano, Oliverio Vargas, Andrés Catalá Isla, Alape Benitez, Germán Rangel
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Stem Cell Research & Therapy
Subjects:
Peripheral arterial disease
Chronic limb-threatening ischemia
Cell therapy
Autologous bone marrow mononuclear cells and allogenic Wharton jelly-derived mesenchymal stem cells
Online Access:https://doi.org/10.1186/s13287-023-03427-z

Internet

https://doi.org/10.1186/s13287-023-03427-z

Similar Items